Brief: Standard BioTools Q2 EPS USD -0.09

Standard BioTools

11/08/2025 21:01

Overview

Standard BioTools Q2 revenue falls 3% yr/yr to $21.8 mln

Adjusted EBITDA beats estimates

Co announces SomaLogic sale to Illumina for up to $425 mln

Outlook

Standard BioTools expects 2025 revenue between $165 mln and $175 mln

Company anticipates 2025 revenue from continuing operations of $78 mln to $83 mln

Standard BioTools targets adjusted EBITDA break-even in 2026

Company sees high single-digit decline in Americas academic revenue due to NIH pressures

Result Drivers

REVENUE DECLINE - Revenue from continuing operations decreased by 3% year-over-year to $21.8 mln, with the decline attributed to capital constraints in global end-markets impacting instrument sales

CONSUMABLES GROWTH - Consumables revenue increased by 18% year-over-year, driven by growth across imaging, flow, and microfluidics product lines

GROSS MARGIN IMPROVEMENT - Gross margins improved to 48.8% in Q2 2025 from 46.1% in Q2 2024, attributed to product mix and improvements from Standard BioTools Business System (SBS)

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$21.80 mln
Q2 EPS
-$0.09
Q2 Net Income
-$33.46 mln
Q2 Adjusted EBITDA
Beat
-$16.10 mln
-$18 mln (3 Analysts)
Q2 Gross Margin
48.8%
Q2 Adjusted Gross Margin
54.1%
Q2 Operating Income
-$25.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Standard BioTools Inc is $1.93, about 32.2% above its August 8 closing price of $1.31

Press Release: ID:nGNX9CNzjp

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)